We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Swab and Viral Transport Medium Market to Reach USD 2.2 Billion by 2030 on Back of COVID-19 Pandemic

By LabMedica International staff writers
Posted on 03 Dec 2020
Print article
Illustration
Illustration
The global swab and viral transport medium (VTM) market was valued at USD 0.9 billion in 2019 and will witness a moderate growth rate of ~3% from 2020 to 2030 to reach USD 2.2 billion by 2030, driven by the onslaught of COVID-19 and increasing R&D activities.

These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.

The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.

In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.

The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.

However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.

Related Links:
Transparency Market Research

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics